ClinicalTrials.gg
RecruitingNCT05769868CIBERbBECHOUpdated Oct 1, 2024

Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments

A Phase 3 interventional study of Esmolol Injection [Brevibloc] in Cirrhosis, Diabetes Mellitus and Oncologic Disorders, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 6 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Primary conditionDiabetes MellitusRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Phase 3, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 254 studies in Diabetes Mellitus with a site in Spain — 20 open to participants now, 29 under way, 5 of them phase 3. Diabetes Mellitus · Spain.

Planned enrollment
49th of 211
1,000 · median 394
Started
2023
with 7 others
Phase 3
94 of 254
2 open now
Primary completion
2027-03
later than 17 of 28 live
Registered
221st of 254
by date

Among the 254 studies in Diabetes Mellitus with a site in Spain, this one is the 49th largest by planned enrollment of the 211 interventional ones that give a count, is one of 8 that started in 2023, is one of 94 in phase 3, reaches primary completion later than 17 of the 28 other live ones, and was the 221st registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

20 of the 254 studies in Diabetes Mellitus with a site in Spain are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 254 studies in Diabetes Mellitus with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and antineoplastic treatments.

Read the detailed description

After being informed about the study and potential risks, all patients giving written informed consent will undergo a 10 days screening period to determine eligibility for study entry. At Baseline, patients who meet the eligibility requirements will be allocate in one of the 4 cohorts according to their medical conditions.

Trial design consists in a Screening period, Baseline, and 6 additional visits until Month-36.

All patients will undergo to a conventional echocardiography and echocardiography with esmolol administration at Baseline. This procedure will be performed at the following visits according their cohort.

Other complementary procedures will be the collection of blood samples to determine biomarkers, as well as hematology and biochemistry, vital signs and another explorations.

03

Conditions studied

  • Cirrhosis
  • Diabetes Mellitus
  • Oncologic Disorders

Browse trials for

Keywords

  • beta blockers
  • echocardiography
  • esmolol
  • systolic function
  • cardiovascular diagnosis
  • biomarkers
  • diagnostic techniques
  • medical imaging
04

In context

Diabetes Mellitus Reclassified

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 80 across 6,027 interventional studies indexed under Diabetes Mellitus.

Browse Diabetes Mellitus studies →

Lead sponsor

Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.

Compared within Diabetes Mellitus, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years.
  2. Absence of previous heart disease, defined as the absence of relevant cardiac structural alterations such as moderate or severe hypertrophy, alteration of segmental contraction, Moderate or severe valvular disease, intraventricular obstructive gradient, or old myocardial infarction.
  3. Existence of an at least acceptable ultrasonic window, which allows the visualization of at least 14 of the 17 segments of the LV myocardium.
  4. Sinus rhythm, with a basal heart rate greater than 50 bpm.
  5. Diabetic patients with a diagnosis of Diabetes Mellitus 2 (DM2) with or without Heart Failure with Normal (HFNEF) (n = 300) will be included. Previous diagnosis of HFNEF with clinical stability at the time of inclusion (n = 200). No previous diagnosis of HFNEF (n = 100).
  6. 200 patients with cirrhosis stratified by the following additional criteria will be included: A class (n = 25); Child-Pugh B class (n = 75); Child-Pugh C class (with and without ascites n = 50 and n = 50, respectively).
  7. 300 cancer patients will be included, divided into 3 therapeutic groups: 125 patients diagnosed with Lymphoma or Sarcoma receiving chemotherapy based on anthracyclines at high doses (≥ 240 mg / m2); 125 patients with Human Epidermal growth factor Receptor 2 () positive breast cancer receiving chemotherapy regimen that includes trastuzumab without anthracyclines; 50 patients with hepatocarcinoma receiving treatment with Sorafenib.
  8. Expected survival> 6 months, first-diagnosis of cancer, and receiving treatment with chemotherapy that includes any of the previous schemes.
  9. A control group (n = 200) without heart disease and without any of the study conditions will be included: diabetes from any cause, cancer or active cancer treatment or some degree of liver disease.

Exclusion criteria

Exclusion Criteria:

  1. for the administration of esmolol (according to technical data sheet): to esmolol hydrochloride; Severe sinus bradycardia (HR \<50 bpm); 2nd or 3rd degree atrioventricular block without pacemaker; Cardiogenic shock, severe hypotension, or decompensated heart failure; Untreated pheochromocytoma; Acute asthmatic attack; Concomitant intravenous administration or within the first 48 hours after verapamil.
  2. Treatment with beta-blocker drugs (oral, topical or intravenous) in the last 7 days before the study.
  3. History of ventricular or supraventricular arrhythmias that prevent the safe withdrawal of antiarrhythmic or braking treatment before the administration of esmolol.
  4. History of previous high-grade atrioventricular (AV) conduction disorder in non-pacemaker patients.
  5. Severe asthma with bronchial hyperresponsiveness.
  6. Patients with acute infection.
  7. Participants in other clinical trials in the 30 days prior to the start of the study.
  8. Pregnant women, or who plan to be, and women during breastfeeding.
  9. Patients with limitation to follow the protocol for any reason.
  10. Diagnosis of Diabetes Mellitus (DM) of any type other than type 2 [type 1, Latent Diabetes in Adults (LADA), Maturity-Onset Diabetes of the Young (MODY), New Onset Diabetes After Transplant (NODAT), etc.]
  11. Patients in (NYHA) functional class IV or with advanced heart failure.
  12. Treatment with an oral beta-blocker at the time of the examination that cannot be safely temporarily suspended 72 hours before the test.
  13. Active evidence of Virus (HBV) or Hepatitis B Virus () infection.
  14. Personal history of previous cancer requiring systemic treatment (excludes skin or localized cancers treated locally surgically).
  15. Previous exposure to systemic antitumor treatment or radiotherapy on the thoracic region.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    Single Arm

    1 conventional echocardiography without esmolol administration followed by 1 echocardiography with esmolol administration at Baseline and other study visits.

    Drug: Esmolol Injection [Brevibloc]

Interventions

  • DrugEsmololStudies of EsmololEsmolol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Brevibloc® will be administered intravenously by infusion pump following the administration schedule: Loading dose of 500 μg/kg for 1 minute, followed by a maintenance infusion of 50 μg/kg/minute over 5 minutes. If the target response is not obtained, the loading dose is repeated and the 50 dose is increased by 50 μg/kg/minute to a maximum of 200 μg/kg/minute. The objective response to esmolol beta-blockade is defined as a 15-20% reduction in heart rate, with lower limits of 55 bpm and a systolic blood pressure not less than 90 mmHg and diastolic blood pressure not less than 50 mmHg. The perfusion is kept active while the echocardiography image acquisition is completed (approx. 15-30 min).

    Also known as: Anatomical Therapeutic Chemical (ATC) code: C07AB09, Esmolol Hydrochloride

07

What researchers measure

Primary outcomes

  1. Left Ventricle (LV) ejection fraction

    Estimated with 3D echocardiography (Both: convectional and with esmolol administration)

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  2. Peak measurement of global LV systolic longitudinal strain

    Estimated with 3D echocardiography (Both: convectional and with esmolol administration)

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  3. Ejection Intraventricular Pressure Difference (EIVPD) measure

    Estimated with M-mode echocardiography (Both: convectional and with esmolol administration)

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

Secondary outcomes

  1. Ejection fraction

    Obtained with 2D echocardiography (Simpson's biplane method)

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  2. Interleukin (IL)-1β

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  3. High-sensitivity IL-6 (hsIL-6)

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  4. Soluble Suppression of Tumorigenicity 2 (ST-2)

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  5. N-terminal fragment of brain natriuretic peptide (NT-proBNP)

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  6. Ultrasensitive troponin I (hsTnI)

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  7. Procollagen type I terminal propeptide (PICP)

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  8. C-terminal telopeptide collagen type I (CITP)

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

  9. Matrix metalloproteinase-1 (MMP-1)

    Biochemical variables in blood in relation to the alteration of the different components of the myocardium

    Time frame: At Baseline (Day 1) until Month-24 according to cohort

08

Study locations

4 of 6 sites recruiting
09

References and documents

Publications

  • Yotti R, Bermejo J, Benito Y, Sanz-Ruiz R, Ripoll C, Martinez-Legazpi P, del Villar CP, Elizaga J, Gonzalez-Mansilla A, Barrio A, Banares R, Fernandez-Aviles F. Validation of noninvasive indices of global systolic function in patients with normal and abnormal loading conditions: a simultaneous echocardiography pressure-volume catheterization study. Circ Cardiovasc Imaging. 2014 Jan;7(1):164-72. doi: 10.1161/CIRCIMAGING.113.000722. Epub 2013 Oct 30. PubMed 24173273 ↗
  • Yotti R, Bermejo J, Desco MM, Antoranz JC, Rojo-Alvarez JL, Cortina C, Allue C, Rodriguez-Abella H, Moreno M, Garcia-Fernandez MA. Doppler-derived ejection intraventricular pressure gradients provide a reliable assessment of left ventricular systolic chamber function. Circulation. 2005 Sep 20;112(12):1771-9. doi: 10.1161/CIRCULATIONAHA.104.485128. PubMed 16172285 ↗
  • Yotti R, Ripoll C, Benito Y, Catalina MV, Elizaga J, Rincon D, Fernandez-Aviles F, Bermejo J, Banares R. Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis. Hepatology. 2017 Jun;65(6):2019-2030. doi: 10.1002/hep.29104. Epub 2017 Apr 28. PubMed 28195341 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Mar 2027, 47 months after the start.

Of 63 non-industry phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 79. This study's planned 47 months is above that.

Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Mar 15, 2023
StartActual
Apr 18, 2023
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05769868
Lead sponsor
Consorcio Centro de Investigación Biomédica en Red (CIBER)
Collaborators
Instituto de Salud Carlos III
Responsible party
Sponsor
First posted
Mar 15, 2023
Start date
Apr 18, 2023
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 1, 2024

Study contacts

Tania Luis García, BS
Contact
tanialuisgarcia@cibercv.es
+34 917996034 ext. 47304
Projects Department (CIBER)
Contact
proyectos@ciberisciii.es
+34 918222874
Javier Bermejo Thomas, MD, PhD
principal investigator · Hospital Universitario Gregorio Marañón

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esmolol

Start the discussion